Ravulizumab treatment outcomes in patients with Generalized Myasthenia Gravis (gMG)
naive to complement inhibitors. Prospective, multicenter, non-interventional study (MG-ARCADIA).

We would like to invite you to participate in a multicenter, observational, open-label study designed to document the management and clinical outcomes of patients with Generalized Myasthenia Gravis (gMG) that received ravulizumab in the scope of routine clinical practice within the frames of National Drug Program. The registration and login panel for the eCRF system is available below.